BenzingaAugust 13, 2026 at 8:06 AM NY22 days ago

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story